Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Congenital Hemophilia with Inhibitors
Congenital Hemophilia with Inhibitors

Clinical pathway for emergent bleeds

This example algorithm was developed by Novo Nordisk in collaboration with experts and follows the latest treatment guidelines. It outlines common steps for treating emergent bleeds in the emergency department (ED) setting.a

Clinical pathway for emergent bleeds

This example algorithm was developed by Novo Nordisk in collaboration with experts and follows the latest treatment guidelines. It outlines common steps for treating emergent bleeds in the emergency department (ED) setting.a

aThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision making. This example is for illustrative purposes and does not constitute guidance for medical advice or treatment.

Now that you’ve reviewed common steps for treating an emergent bleed, you may be interested in an illustrative patient case example.

Now that you’ve reviewed common steps for treating an emergent bleed, you may be interested in an illustrative patient case example.

References:

  1. Centers for Disease Control and Prevention. Hemophilia. https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html. September 6, 2018. Accessed February 4, 2021.
  2. National Hemophilia Foundation. Guidelines for emergency department management of individuals with hemophilia and other bleeding disorders, #257. New York, NY: National Hemophilia Foundation; 2019.
  3. Riley L, Womack M, Zappa S. Emergency Room Care. In Nurses' guide to bleeding disorders. New York, NY: National Hemophilia Foundation; 2012.
  4. Berntorp E, Shapiro A, Astermark J, et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006;12(suppl 6):1-7.
  5. DiMichele DM. Inhibitors in Hemophilia: A Primer. 4th ed. Montréal, Québec, Canada: World Federation of Hemophilia; 2008:1-9.
  6. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.
  7. National Hemophilia Foundation. Recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors, #258. New York, NY: National Hemophilia Foundation; 2020.
  8. Center for Disease Control and Prevention. Hemophilia Treatment Center (HTC) Directory. https://www2a.cdc.gov/ncbddd/htcweb/Dir_Report/Dir_Search.asp. Accessed September 18, 2019.